Nestlé and Danone submit bid for Pfizer's infant nutrition unit
Nestlé and Danone have submitted bids for Pfizer's infant nutrition unit, which puts Europe's leading food companies in competition for the division.
A tax-free spin off the unit by Pfizer may also be an option. In September, it was reported that Pfizer has delayed the sending of sales documents to potential buyers in order to evaluate a spin-off.
As of June, Nestlé had $8.3bn in cash, cash equivalents and short-term investments, more than twice compared to Danone's $3bn, Bloomberg reported.
The sale of the unit, which posted sales of $1.9bn in 2010, is expected to fetch as much as $10bn.
Potential buyers may face antitrust issues in some markets. With the Pfizer division, Nestlé would hold more than 60% of the market for baby formula in Australia, Mexico and elsewhere, while Danone would hold 80% of the market in the UK, Turkey and New Zealand and more than 70% in Ireland and Australia
Pfizer gained ownership of the infant nutrition unit in 2009, when it acquired pharmaceutical company Wyeth for $68bn.
In July, Pfizer said that it plans to sell its infant nutrition unit and animal health division, following its review of businesses that are not associated with drug discovery.

Comments may be moderated for spam, obscenities or defamation.